Conditions: Alpha-1 Antitrypsin Deficiency
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 36
Healthy volunteers: no

Brief summary:
To evaluate different doses of "Kamada-AAT for Inhalation" on the levels of alpha 1-proteinase inhibitor and other analytes in epithelial lining fluid (ELF) and serum and to assess the safety of the treatment in subjects with AAT Deficiency.

Detailed description:

Arms:
arm 1: Daily inhalation of Kamada-AAT for Inhalation, 80mg arm 2: Placebo administered by inhalation daily arm 3: Daily inhalation of Kamada-AAT for Inhalation, 160mg

Interventions: intervention 1: Kamada-AAT for Inhalation, 80mg intervention 2: Placebo intervention 3: Kamada-AAT for Inhalation, 160mg
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: